Published 2022 | Version v1
Publication

IMMUNE TUMOR MICROENVIRONMENT (I-TME) ANALYSES IN METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS (PTS) TREATED WITH SECOND LINE NIVOLUMAB: RESULTS FROM THE MEET-URO 18 STUDY

Additional details

Created:
February 13, 2024
Modified:
February 13, 2024